Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurogesX Q4 net loss declines to $4.79m
NeurogesX, a biopharmaceutical company, has reported a net loss attributable to common stockholders of $4.79m, or $0.27 per share, for the fourth quarter of 2008, compared to a
NeurogesX, a biopharmaceutical company, has reported a net loss attributable to common stockholders of $4.79m, or $0.27 per share, for the fourth quarter of 2008, compared to a
Eli Lilly and Company has reported that the FDA has approved a new indication for Symbyax. Symbyax is now reported to be the first drug approved by the
SemBioSys Genetics, a Canadian biotechnology company, has reported positive preliminary results of its first ‘in-man’ clinical study of SBS-1000, a recombinant human insulin manufactured using its proprietary platform.
Oncolytics Biotech has reported positive interim clinical results from its Phase I/II UK trial of Reolysin combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigator for
Falberg’s appointment brings the number of board members to seven who will all stand for reelection at the Annual General Meeting of Shareholders on May 5, 2009. Falberg
Pursuant to the terms of contract, Bristol-Myers will implement Mobile Intelligence, Cegedim’s customer relationship management (CRM) solution, to its neurosciences sales team. The new agreement also includes the
Phadia, a developer and marketer of blood test systems, has launched the Phadia Immunology Reference Laboratory, or PiRL, the result of a research collaboration between the company and
The collaboration focuses on validating certain gene targets using small interfering RNA (siRNA) provided by Bristol-Myers Squibb and employing Tekmira’s stable nucleic-acid lipid particle (SNALP) formulations to deliver
Mr Enright has served as president of the Canadian Investor Relations Institute since November 2008. In September 2008, Mr Enright retired from his position as president and CEO
MDRNA, a biotechnology company, has reported a net loss of $12.30m or $0.39 per share, for the fourth quarter of 2008, compared to a net loss of $12.01m